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The Relation of Thyroid Function to Components of the 
Metabolic Syndrome in Korean Men and Women
This study was to assess the relation of thyroid dysfunction to metabolic syndrome (MetS) 
at an earlier stage in Korean population. Metabolic parameters such as body composition, 
blood pressure (BP), fasting glucose, total cholesterol, triglyceride (TG), HDL-cholesterol 
(HDL-C), LDL-cholesterol (LDL-C), thyroid-stimulating hormone (TSH) and free thyroxine 4  
(fT4) were measured. During a mean follow-up of 3 yr, 5,998 Koreans ages over 18 yr were 
assessed. There were 694 cases of MetS at follow-up. The mean age of the subjects was 
45.6 ± 9.5 yr. Mean level of TSH was 2.02 ± 1.50 mIU/L, mean level of fT4 was 1.23 ± 
0.20 ρM/L. At baseline, TSH levels and fT4 levels were associated to waist circumference, 
BP, glucose and lipids in the subjects. Increase in systolic blood pressure, diastolic blood 
pressure (DBP), total cholesterol and TG were significantly associated with changes in TSH 
levels after adjustment. Changes in DBP, TG, HDL-C and fasting glucose were significantly 
associated with changes in fT4 levels after adjustment. Increase in TSH levels even after 
further controlling for baseline TSH level predicted the MetS over the study period. In 
conclusion, there is a relationship between thyroid function and cardiovascular risk factors, 
such as BP, total cholesterol, TG, HDL-C and fasting glucose. Also, higher levels of TSH 
may predict the MetS in Korean. 
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INTRODUCTION 
Hypothalamic corticotrophin-releasing hormone (CRH) plays 
an important role in inhibiting gonadotropin-releasing hormone 
secretion during stress, while via somatostatin it also inhibits 
growth hormone, thyrotropin-releasing hormone and thyrotro-
pin secretion, suppressing thus reproduction, growth and thy-
roid function (1). Excessive and sustained cortisol secretion or 
chronic administration of pharmacologic doses of glucocorti-
coids have been long associated with depression, hypertension, 
osteoporosis, immune suppression and the entire spectrum of 
the metabolic syndrome (MetS), including visceral obesity, in-
sulin resistance, dyslipidemia, dyscoagulation and hyperten-
sion, along with their morbid sequelae of atherosclerosis and 
cardiovascular disease (CVD) (2-4). Each of these manifesta-
tions could in theory be produced, despite the presence of nor-
mal, nonhyperfunctioning HPA (Hypothalmo-pituitary-adre-
nal) axis, by tissue-specific hypersensitivity to glucocorticoids 
of, the amygdala or mesocorticolimbic system, cardiovascular 
system, bone, immune system or adipose tissue (5). 
  Thyroid disease is associated with atherosclerotic CVD (6-8). 
However, there is controversy as to whether this association is 
also present in subclinical hypothyroidism (7, 9, 10). It is known 
that over hypothyroidism leads to an increase in plasma choles-
terol levels and blood pressure (BP) (9, 10). Most studies in sub-
clinical hypothyroidism show comparable but less pronounced 
associations (11, 12). Most subjects at risk for CVD are euthyroid. 
Moreover, little is known about the relationship between insu-
lin resistance and thyroid function. In a cross-sectional study in 
47 healthy euthyroid subjects, it was found that insulin resistance 
modified the relationship between levels of thyroid-stimulating 
hormone (TSH) and low-density lipoprotein cholesterol (LDL-
C) (13). A similar study in 117 diabetic patients revealed a com-
parable interaction between thyroid function and insulin sensi-
tivity in contributing to diabetic dyslipidemia (14). Also, a recent 
study showed that low normal free thyroxine 4 (fT4) levels were 
significantly associated with hyperlipidemia and increased in-
sulin resistance. These findings are consistent with an increased 
cardiovascular risk in subjects with low normal thyroid function 
(15). However, a longitudinal study has not yet been performed 
to assess a possible role for thyroid dysfunction in terms of met-
abolic abnormality. We aimed to investigate the relationships 
between thyroid function and MetS components and whether 
thyroid function predicts the MetS in a large sample of Korean 
population with normal thyroid function as a prospective co-
hort study.  Park SB, et al.  •  Thyroid Function and Metabolic Syndrome   
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MATERIALS AND METHODS
Study population 
We enrolled 7,757 Koreans ages over 18 yr who had undergone 
medical evaluation two times or more at Ajou University Hos-
pital between May 2002 and February 2009. 
  To avoid confounding of the association between thyroid func-
tion and the risk of preexisting MetS, 1,271 subjects with MetS 
and 35 patients with hypothyroidism or hyperthyroidism dur-
ing the enrollment period were excluded. In addition, 453 sub-
jects with history of thyroid disease, cancer or antithyroid treat-
ment were excluded. The final sample included 5,998 subjects. 
Data collection 
The sociodemographic characteristics of subjects were assessed 
by questionnaire. Life style factors such as smoking status, alco-
hol intake, and exercise were assessed as well. Height and weight 
were measured using bioelectrical impedance analysis (Inbody 
3.0, Biospace, Seoul, Korea) following overnight fast. Body mass 
index (BMI) was calculated as weight divided by height squared 
(kg/m
2) (16). Waist circumference (WC) was measured at mid-
dle part between the lower rib and iliac crest by a trained nurse. 
Blood pressure was measured electrically (TM-2650A, PMS In-
struments, Tokyo, Japan) after a rest of at least 15 min.
  Venous blood was drawn following an 8-hr overnight fast and 
24-hr abstinence from vigorous activity. Standard enzymatic 
measurements of total cholesterol, triglycerides, high-density 
lipoprotein cholesterol, and fasting glucose were made on fresh 
serum samples by oxidase–peroxidase enzymatic assay (TBA-
200FR, Toshiba, Tokyo, Japan). TSH and fT4 were measured us-
ing a radioimmunoassay. The reference ranges were 0.25-5.0 
mIU/L for TSH and 0.7-1.8 ρM/L for fT4. 
Outcome definition and follow-up procedures 
We defined thyroid function status of the subjects by level of thy-
roid hormones so we divided the cohort into hypothyroidism 
(fT4 < 0.7 ρM/L), subclinical hypothyroidism (TSH > 5.0 mIU/L 
and normal fT4 level), subclinical hyperthyroidism (TSH < 0.25 
mIU/L and normal fT4 level), hyperthyroidism (fT4 > 1.8 ρM/L), 
and euthyroid state. We followed the National Cholesterol Edu-
cation Program Adult Treatment Panel III (NCEP-ATP III) guide-
line component to define MetS, but the WC cutoff point for cen-
tral obesity in Koreans, which was 90 cm for men and 85 cm for 
women (17). The last follow-up was conducted on 28 February 
2009, and the mean follow-up period was 2.96 yr. 
Statistical analysis
We used multiple linear regression analyses to assess the rela-
tionship between cardiovascular risk factors and thyroid func-
tion at baseline, adjusting for age, gender, BMI, smoking status, 
alcohol intake and exercise habits. Linear regression analyses 
were also used to assess effects of cardiovascular risk factors as 
predictors of changes in thyroid function, controlling for age, 
gender, BMI, smoking status, alcohol intake, exercise habits, 
baseline level of thyroid function and the baseline level of each 
metabolic factors. Logistic regression analyses were used to eval-
uate associations of changes in thyroid function status to MetS 
at follow up, while controlling for age, gender, BMI, smoking 
status, alcohol intake and exercise habits. In all analyses, a two-
sided α level of 0.05 was considered statistically significant. All 
analyses were conducted with the use of SPSS software (SPSS 
Inc., Chicago, IL, USA), in version 12.0.
Ethics statement 
The institutional review boards of Ajou University approved the 
study (AJIRB-MED-MDB-10-022). In the IRB approval, informed 
consent from the survey participants was waived. 
RESULTS
Demographic characteristics 
Demographic characteristics are presented in Table 1. The total 
of 5,998 individuals included 57.8% men (n = 3,469) and 42.2% 
women (n = 2,529). The mean age of the subjects was 45.6 ± 9.5 
yr. The mean level of TSH was 2.02 ± 1.50 mIU/L, the mean level 
of fT4 was 1.23 ± 0.20 ρM/L. Men, in comparison to women, had 
higher smoking and alcohol drinking rates. Over 3 yr of follow-
up, there were 694 incident cases (11.6%) of MetS (507 in men, 
187 in women). 
Correlations between TSH levels, fT4 levels and 
cardiovascular risk factors at baseline 
TSH levels were negatively associated to WC, the association 
that remained significant after adjustment for age, gender, BMI, 
smoking status, alcohol intake, and exercise, while TSH levels 
were positively associated to TG after controlling for age, gen-
der, and even after further adjustment. There was a significant 
correlation between HDL-C and TSH levels after adjustment.
  fT4 levels were positively associated to WC and diastolic blood 
pressure (DBP), the association that remained significant after 
adjustment for age, gender, BMI, smoking status, alcohol intake, 
and exercise. fT4 levels were also positively associated to systolic 
blood pressure (SBP), but this association was reduced to non-
significance after adjustment. fT4 levels were negatively associ-
ated to TG after adjustment, while HDL-C was positively asso-
ciated with fT4 levels after adjustment. There were no associa-
tions between thyroid function and total cholesterol, LDL-cho-
lesterol and fasting glucose with or without adjustment (Table 2). 
Changes in cardiovascular risk factors in the prediction of 
changes in thyroid function  
To assess the associations between cardiovascular risk factors Park SB, et al.  •  Thyroid Function and Metabolic Syndrome     
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and thyroid function, linear regression models were conducted, 
controlling for age, gender, the baseline level of thyroid function 
and the baseline level of each metabolic factors. As Table 3 shows, 
higher SBP, DBP, total cholesterol, TG, and fasting glucose were 
significantly associated with changes in TSH levels. Further ad-
justments for BMI, smoking status, alcohol intake and exercise 
habits showed that changes in SBP, DBP, total cholesterol and 
triglyceride were still positively associated with changes in TSH 
levels. 
  As seen Table 4, higher DBP, total cholesterol, HDL-C, LDL-C 
and fasting glucose, and lower triglyceride were significantly 
associated with changes in fT4 levels. Further adjustments for 
BMI, smoking status, alcohol intake and exercise habits showed 
that changes in DBP, triglyceride, HDL-C and fasting glucose 
were still associated with changes in fT4 levels. 
Correlations between thyroid function, insulin and HOMA
Insulin and homeostatis model assessment of insulin resistance 
Table 1. General characteristics of the study population at baseline
Parameters
Men (n = 3,469) Women (n = 2,529)
Baseline Follow-up Baseline Follow-up
Age (yr) 45.6 ± 9.3 48.6 ± 9.5 45.6 ± 9.7 48.5 ± 9.8
Weight (kg) 69.3 ± 8.5 69.7 ± 8.6 56.5 ± 7.5 56.5 ± 7.3
Waist circumference (cm) 83.6 ± 6.7 84.6 ± 7.0 75.9 ± 7.5 79.4 ± 7.9
BMI (kg/m
2) 23.9 ± 2.5 24.1 ± 2.5 22.8 ± 2.8 22.9 ± 2.8
SBP (mmHg) 120.9 ± 14.7 119.9 ± 13.5 114.2 ± 16.1 115.0 ± 15.3
DBP (mmHg)   76.9 ± 10.8 79.5 ± 10.1   72.0 ± 10.2 72.8 ± 10.6
Total cholesterol (mg/dL) 192.0 ± 32.9 190.5 ± 32.5 186.8 ± 34.9 186.9 ± 33.7
Triglyceride (mg/dL)  132.1 ± 81.8 128.3 ± 76.2  93.0 ± 49.0 91.9 ± 51.2
HDL cholesterol (mg/dL)  52.4 ± 11.5  52.8 ± 12.0  60.2 ± 12.8  60.9 ± 13.2
LDL cholesterol (mg/dL) 113.5 ± 29.6 112.2 ± 29.3 108.0 ± 31.3 107.6 ± 30.3
Fasting glucose (mg/dL) 99.4 ± 18.4 97.5 ± 16.4   93.8 ± 12.6   91.9 ± 13.5
Insulin (µIU/mL)  6.41 ± 3.61  6.79 ± 3.78   7.69 ± 4.38   6.65 ± 3.56
HOMA-IR 1.57 ± 0.92    1.70 ± 1.04   1.80 ± 1.07    1.57 ± 1.040
TSH (mIU/L) 1.79 ± 1.08  1.78 ± 1.23   2.33 ± 1.89  2.22 ± 1.74
fT4 (ρM/L) 1.27 ± 0.20 1.34 ± 0.19 1.17 ± 0.18  1.23 ± 0.19
Smoking status 65.6%   7.6%
Alcohol intake  76.3% 33.3%
Regular exercise  19.1% 17.9% 18.6% 17.3%
Values are mean ± SD unless otherwise indicated. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low 
density lipoprotein; HG, hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; TSH, thyroid stimulating hormone; fT4, free thyroxine 4. 
Table 2. Associations of thyroid function with serum lipid concentrations and the 
components of the metabolic syndrome at baseline 
Parameters Model
TSH fT4
β P β P
Waist circumference 1
2
3
-0.095
-0.030
-0.083
0.000
0.043
0.002
0.120
0.043
0.155
< 0.001
0.003
< 0.001
SBP 1
2
3
-0.014
0.008
0.008
0.278
0.543
0.612
0.026
0.015
0.027
0.047
0.249
0.092
DBP 1
2
3
-0.011
0.019
0.023
0.404
0.144
0.145
0.128
0.111
0.121
< 0.001
< 0.001
< 0.001
Total cholesterol 1
2
3
0.010
0.011
0.016
0.428
0.391
0.309
0.007
0.020
0.019
0.596
0.090
0.200
Triglyceride 1
2
3
0.010
0.057
0.068
0.437
0.000
0.000
0.002
-0.056
-0.049
0.906
< 0.001
0.001
HDL cholesterol 1
2
3
0.010
-0.047
-0.041
0.418
0.000
0.011
-0.009
0.069
0.034
0.487
< 0.001
0.029
LDL cholesterol 1
2
3
0.003
0.006
0.003
0.811
0.624
0.840
0.008
0.019
0.026
0.539
0.145
0.085
Fasting glucose 1
2
3
-0.024
-0.004
-0.007
0.068
0.780
0.665
0.021
0.004
0.006
0.102
0.756
0.686
Values of β are standardized regression coefficients: model 1, crude; model 2, after 
adjustment for age and gender; model 3, further adjustment for BMI, smoking status, 
alcohol intake and exercise; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HDL, high density lipoprotein; LDL, low density lipoprotein.
Table 3. Summary of results from 8 standardized multiple linear regression coeffi- 
cients predicting change in TSH levels 
Predictor variables* B SE β
† P
Change in waist circumference 0.001 0.004 0.005 0.678
Change in systolic blood pressure 0.005 0.001 0.045 0.001
‡
Change in diastolic blood pressure  0.008 0.002 0.050 < 0.001
‡
Change in total cholesterol 0.002 0.001 0.042 0.001
‡
Change in triglyceride 0.001 0.000 0.048 < 0.001
‡
Change in HDL cholesterol 0.001 0.002 0.007 0.561
Change in LDL cholesterol 0.001 0.001 0.016 0.201
Change in fasting glucose 0.005 0.002 0.041 0.001
*Computed as difference between baseline and follow-up levels. Results are based on 
5,998 individuals with complete data; 
†Adjusted for age, gender, baseline TSH level, 
and the baseline level of each metabolic factors; 
‡P < 0.01 controlling for age, gender, 
BMI, baseline TSH level, the baseline level of each metabolic factors, smoking status, 
alcohol intake and exercise. B, unstandardized regression coefficients; SE, standard 
error.Park SB, et al.  •  Thyroid Function and Metabolic Syndrome   
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(HOMA-IR) measures were only available in a subpopulation 
of the study participants (n = 1,173). The mean insulin level of 
the subjects was 6.4 ± 3.6 μIU/mL. At baseline, the associations 
of TSH and fT4 to insulin and HOMA were not significant, ad-
justing for age, gender and BMI. 
  Over a 3 yr follow-up, higher levels of TSH was significantly 
associated with changes in insulin levels and HOMA-IR after 
controlling for age, gender, BMI, the baseline TSH level and the 
each baseline variable factors, smoking status, alcohol intake and 
exercise (β = 0.166, P = 0.008, β = 0.164, P = 0.008, respectively). 
Lower levels of fT4 was significantly associated with changes in 
HOMA-IR after controlling for age, gender, BMI, the baseline 
fT4 level and the baseline HOMA-IR (β = -0.143, P = 0.016). Fur-
ther adjustments for smoking status, alcohol intake and exercise 
reduced the association of fT4 to HOMA-IR non-significant. 
There was no relation of change in fT4 levels to change in insu-
lin levels with or without adjustment (n = 326). 
 
Associations of changes in thyroid function to the 
metabolic syndrome 
The associations of changes in thyroid function to the MetS were 
examined in separate logistic regression models that controlled 
for age, gender, BMI, smoking status, alcohol intake, exercise, 
and baseline level of each thyroid function (Table 5). The MetS 
was significantly associated with increase in TSH levels over the 
study period after adjustment. fT4 levels, and individuals with 
subclinical hypothyroidism (n = 158), subclinical hyperthyroid-
ism (n = 49), or overt thyroid dysfunction (n = 38) did not pre-
dict the MetS after adjustment. 
DISCUSSION
In the current study, we found a significant relationship between 
levels of thyroid hormones and cardiovascular risk factors as 
repoted in previous cross-sectional studies (9, 15), as well as over 
the follow-up period. Our results also indicate that higher levels 
of TSH may predict the MetS in this study subjects, suggesting 
that the influence of thyroid function on metabolic abnormality 
extends into subjects without MetS. These findings might be im-
plicated that subjects with low or high normal thyroid function 
are already at increased cardiovascular risk. Bakker et al. (13) 
found that TSH seemed to affect this important cardiovascular 
risk factor especially in subjects who are already at risk of devel-
oping cardiovascular disease because of their insulin-resistant 
state. They showed that a regression model consistent with a vir-
tual absence of an association between TSH with LDL-C in very 
insulin-sensitive subjects, whereas in insulin-resistance subjects 
a steep association exits. A recent cross-sectional study also re-
ported that a close relationship between TSH and MetS in eu-
thyroid postmenopausal women (18).
  Thyroid hormones play an essential role in a variety of meta-
bolic and developmental processes in human body. Most effects 
are mediated via mechanisms that stimulate resting metabolic 
rate, increase ATP expenditure, and modulate adrenergic recep-
tor number and thus responsiveness to catecholamines. Thy-
roid hormones also influence carbohydrate metabolism in skel-
etal muscle and adipose tissue via the positive transcriptional 
regulation of the muscle/fat-specific GLUT4, and stimulate li-
polysis. All these steps interact with insulin action (19). Other-
wise, the pathophysiological process behind the influence of 
thyroid function on lipid metabolism is known from subjects 
with overt thyroid dysfunction. The elevation of TGs in hypo-
thyroidism is caused by a reduced removal rate of TG from plas-
ma due to a decrease in the activity of hepatic TG lipase (20, 21). 
In addition, studies investigating thyroid hormone receptors in 
obese individuals demonstrated a decrease in thyroid hormone 
receptor density (22, 23). Over 3 yr of follow-up, our results show-
ed the associations of thyroid hormones to cardiovascular fac-
tors. Similarly, several important cardiovascular risk factors have 
been identified in patients with mild and subclinical hypothy-
roidism: diastolic dysfunction (24), increased arterial stiffness 
(25), endothelial dysfunction (26), and increase in systemic vas-
cular resistance (27). 
  Unfortunately, insulin resistance was only available in a sub-
sample of the participants. In this group, we found higher levels 
of TSH to be associated with increased insulin resistance, an as-
sociation that remained after adjustment for the confounding 
factors. On contrary, lower levels of fT4 tended to be associated 
Table 4. Summary of results from 8 standardized multiple linear regression coefficients 
predicting change in fT4 levels 
Predictor variables* B SE β
† P
Change in waist circumference 0.000 0.000 0.007 0.540
Change in systolic blood pressure 0.002 0.000 0.000 0.999
Change in diastolic blood pressure  0.001 0.000 0.031   0.009
‡
Change in total cholesterol 0.000 0.000 0.024  0.033
Change in triglyceride 0.000 0.000 -0.043 < 0.001
‡
Change in HDL cholesterol 0.002 0.000 0.061 < 0.001
‡
Change in LDL cholesterol 0.000 0.000 0.021  0.068
Change in fasting glucose 0.001 0.000 0.037    0.001
‡
*Computed as difference between baseline and follow-up levels. Results are based on 
5,998 individuals with complete data; 
†Adjusted for age, gender, baseline fT4 level, 
and the baseline level of each metabolic factors; 
‡P < 0.01 controlling for age, gender, 
BMI, baseline fT4 level, the baseline level of each metabolic factors, smoking status, 
alcohol intake and exercise. B, unstandardized regression coefficients; SE, standard 
error.
Table 5. Summary of results for independent logistic regression analyzes of different 
metabolic markers predicting metabolic syndrome
Predictor variables* B SE P
Change in TSH levels
† 1.103 0.048 0.041
Change in fT4 levels
† 1.144 0.278 0.629
Subclinical hypothyroidism
‡ 0.637 0.387 0.244
Subclinical hyperthyroidism
‡ 0.790 0.671 0.725
*controlled for age, gender, BMI, smoking status, alcohol intake and exercise; 
†further 
adjustment for baseline level of each thyroid function; 
‡compared to euthyroid state.Park SB, et al.  •  Thyroid Function and Metabolic Syndrome     
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with insulin resistance after adjustment. According to a experi-
mental study, a mutation in the α-isoform of the thyroid hor-
mone receptor has been recently described to lead to thyroid 
hormone resistance, low heart rate, and insulin resistance in an 
animal model (28).
  Our results indicate that the MetS was significantly associat-
ed with increase in TSH levels after adjustment over time, even 
though the study individuals at baseline were relatively healthy 
without thyroid disease and MetS. However, fT4 levels, and in-
dividuals with subclinical hypothyroidism or subclinical hyper-
thyroidism did not predict the MetS after adjustment in the study. 
Previous epidemiological studies in which cardiovascular mor-
bidity and mortality have been evaluated in patients with mild 
thyroid hormone deficiency have yielded conflicting data (7, 29, 
30). These results may be due to differences in the study popu-
lations in terms of age, sex, race, definition of mild hypothyroid-
ism, and differences in the duration of follow-up. The weak cor-
relations between thyroid function and metabolic markers in the 
present study probably reflect the extensive metabolic screen-
ing of our subjects to exclude individuals with MetS or thyroid 
disease. Although we did not evaluate status of insulin resistance 
intended for in whole subjects, our results suggest that impair-
ment of thyroid function is metabolically fluctuant if insulin re-
sistance in body might not be progressed but still associated with 
cardiovascular risk factors. 
  The limitation of this study was that the study population con-
sisted of patients who visited a University Hospital. Therefore, 
the prevalence of MetS in our data does not reflect that in gen-
eral population. However, we performed the current study with 
a relatively large number of subjects and also followed up the 
individuals over the study period. Another point of consideration 
is that we did not examine insulin resistance of the subjects us-
ing standard method like hyperinsulinemic euglycemic clamp 
even in subgroup analysis. But we excluded subjects with MetS 
as well as thyroid disease during the enrollment period. Further 
larger randomized trials are necessary to evaluate the potential 
benefit for the management of thyroid dysfunction at an ealier 
stage. 
  In conclusion, the results of the present study show that there 
is a relationship between thyroid function and cardiovascular 
risk factors, such as BP, total cholesterol, TG, HDL-C and fasting 
glucose. Also, higher levels of TSH may predict the MetS in Ko-
rean. 
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This study was to assess the relation of thyroid dysfunction to metabolic syndrome at an earlier stage in Korean population (mean 
follow-up of 3 yr, 5,998 Koreans, age > 18). There were 694 cases of metabolic syndrome at follow-up. Increase in blood pressure 
and cholesterol were associated with TSH levels. Also, some parameters of blood pressure and cholesterol were associated with 
thyroid hormone (fT4) levels. As a whole, there is a relationship between thyroid function and cardiovascular risk factors. Higher 
levels of TSH might predict the metabolic syndrome in Korean.